To report the compassionate use of the Seraph® 100 Microbind® affinity blood filter in a pediatric patient with refractory septic shock caused by invasive Streptococcus pyogenes, highlighting the urgency and innovative nature of this treatment.
Key Findings:
Hemoperfusion was initiated 42 hours after PICU admission.
Post-treatment, there was a reduction in vasoactive support and improvement in metabolic parameters within 24-48 hours.
The patient stabilized without requiring veno-arterial extracorporeal membrane oxygenation, but early severe peripheral ischemia led to bilateral lower-limb amputations.
Interpretation:
Pathogen-binding hemoperfusion with the Seraph® 100 filter showed potential as an adjunctive therapy in refractory pediatric septic shock, although causality cannot be established. This suggests a need for further research into its implications for clinical practice.
Limitations:
Single case study limits generalizability.
No control group for comparison.
Lack of long-term follow-up data on the patient's recovery.
Conclusion:
The findings suggest a potential role for hemoperfusion in selected cases of refractory septic shock, warranting further prospective studies to assess safety and efficacy, while cautioning against overinterpretation due to the single case nature of the study.
